List view / Grid view
2 October 2015 | By Victoria White
Understanding how genomic variants contribute to disease may help clinicians develop improved diagnostics and treatments, in addition to new methods of prevention...
1 October 2015 | By Victoria White
Scientists have uncovered a relationship between a chemical that helps transmit signals in the brain and genetic mutations present in a subset of individuals with autism...
1 October 2015 | By Victoria White
The TaNeDS programme provides close partnership between successful applicants and scientists in Daiichi Sankyo to tackle unmet medical needs...
1 October 2015 | By Victoria White
If further studies show this route can benefit patients, it could help crack one of the toughest challenges in cancer research – how to stop tumours spreading...
30 September 2015 | By Victoria White
BLU-554, an exquisitely selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), is currently being evaluated in a Phase 1 clinical trial in patients with advanced hepatocellular carcinoma...
30 September 2015 | By Victoria White
APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer...
30 September 2015 | By Victoria White
Development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease...
30 September 2015 | By Victoria White
The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies...
29 September 2015 | By Victoria White
Congenica’s platform Sapientia has been developed to analyse and interpret whole genome data. With this grant Congenica will be able to extend its capability to include other types of -omics data...
29 September 2015 | By Victoria White
LA Cell has exclusively licensed technology that enables modified monoclonal antibodies to penetrate into cells and target "undruggable" disease-causing molecules...
29 September 2015 | By Victoria White
The funds will enable Apitope to progress the clinical development of its innovative pipeline which includes therapies for Factor VIII intolerance in Haemophilia A patients...
29 September 2015 | By Victoria White
Preclinical data showed that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation...
29 September 2015 | By Victoria White
LDC and Infinity will work together to select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network...
28 September 2015 | By Victoria White
The newly described Cpf1 system differs in several important ways from Cas9, with significant implications for research and therapeutics...
28 September 2015 | By Victoria White
The $5.5 million grant will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor...
